

BOOK OF ABSTRACTS

POLYMERS IN MEDICINE & BIOLOGY

NOVEMBER 28 – DECEMBER 1, 2022
EMBASSY SUITES BY HILTON NAPA VALLEY
NAPA, CA USA

Co-Chairs:


Prof. Buddy D. Ratner
University of Washington,
Engineered Biomaterials
(UWEB)
Email: ratner@uw.edu

Prof. Theresa M. Reineke
Department of Chemistry
University of Minnesota
Email: treineke@umn.edu

This Book Includes:

Sponsors
Future Workshops
Program
Lecture Abstracts
Poster Abstracts

The recording or photographing of any part of the conference is not permitted without the expressed written consent of the ACS Division of Polymer Chemistry.



ACS
Chemistry for Life®

21.

GLY-200: A novel polymer therapeutic for metabolic diseases

Thomas H. Jozefiak

Glyscend, Inc, 600 Suffolk Street, Suite 250, Lowell, MA 01854

Glyscend Therapeutics is pioneering a new generation of orally administered polymer therapies that safely and temporarily modify the mucosal lining of the gastrointestinal tract. Glyscend's first clinical candidate, GLY-200, was designed to elicit an immediate improvement in type 2 diabetes (T2D) by a mechanism related to certain bariatric surgical procedures (e.g., Roux-en-Y gastric bypass) and duodenojejunal bypass liners (e.g., Endobarrier®). These procedures/devices produce a rapid therapeutic response in part through exclusion of the duodenum from the path of nutrient flow ("duodenal exclusion"). By crosslinking with mucin in the gastrointestinal tract and enhancing its barrier function, GLY-200 creates a pharmacological duodenal exclusion that modulates signaling in the duodenum. In several rat models of T2D, GLY-200 significantly reduced postprandial hyperglycemia. In preclinical studies, GLY-200 was found to be non-absorbed (excreted in feces) and well tolerated. In a phase-1 clinical trial, the safety and tolerability of GLY-200 was confirmed, and the drug is currently under investigation in a phase-2 trial in T2D patients under an IND.

